Karen Reckamp The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol initiated by the National Cancer Institute (NCI), the NCI’s National Clinical Trials Network…
Ryan Scott Eric Kumar Singhi, MD, discusses the current therapeutic landscape and unmet needs in small cell and non–small cell lung cancer. Treatment for patients with limited-stage small cell lung cancer (LS-SCLC) has historically been limited in its activity, but findings from the first planned interim analysis of the phase 3 ADRIATIC study (NCT03703297),…
Mary Redman, PhD Squamous cell cancer (SqCC) of the lung has limited targeted therapy options, making molecular characterization through next-generation sequencing (NGS) beneficial for identifying potential targets. In the Lung-MAP SWOG S1400 trial, Mary Redman, PhD, and colleagues analyzed NGS data from 1,672 patients with stage 4 or recurrent SqCC, sequencing 313 cancer-related genes.…
Vera Kovacevic, PhD The Foundation for the National Institutes of Health (FNIH) has made significant strides in the field of precision medicine with its innovative Lung-MAP (Master Protocol for Treatment of Non-Small Cell Lung Cancer) program. Lung-MAP is a pioneering clinical trial designed to simultaneously test multiple treatments for non-small cell lung cancer (NSCLC) under…
Greg Laub In this exclusive MedPage Today video, Karen Reckamp, MD, of Cedars-Sinai Medical Center in Los Angeles, discusses the study design of the innovative phase III Pragmatica-Lungopens in a new tab or window trial (S2302) in metastatic non-small cell lung cancer (NSCLC). Pragmatica-Lung was built on phase II findings from the Lung-MAP platformopens…
A report suggests that Lung-MAP, which for almost a decade has undergirded the first NCI-sponsored precision medicine clinical trial in lung cancer, can serve as a model for future clinical research that is more rapid, innovative, and inclusive. Three members of the team that conceived that trial—the Lung Cancer Master Protocol, or Lung-MAP—discuss lessons learned…
Matthew Bin Han Ong Monica Bertagnolli is “someone who goes up against the odds and has confidence that we can do it,” FDA Commissioner Robert Califf said of the newly confirmed NIH director at a recent annual meeting of the Friends of Cancer Research (The Cancer Letter, Nov. 10, 2023). “It may take a…
The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP trial was the first National Cancer Institute (NCI)-sponsored precision medicine clinical…
Ashling Wahner Developments in the management of lung cancer include novel targets that may continue to move the needle in the direction of increasingly targeted therapies for patients with small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC), according to Apar Kishor Ganti, MD. “Although SCLC is difficult to treat, there is…
